Precision Combination Therapy is a therapeutic strategy in oncology that belongs to the class of combination cancer therapies and is distinguished by its integration of biomarker-driven patient selection with rationally designed drug combinations to target specific molecular vulnerabilities in individual tumors.
15
Publications
1.3K
Citations
170
Authors
68
Institutions
Publications per year
2017–2026
10
Parents
Publications
15
1–5 of 15
Authors
170
- SK
2
h-index
- CW
2
h-index
- BL
2
h-index
- RKRazelle Kurzrock
The University of Texas MD Anderson Cancer Center, United States
2 publications · 732 citations
2
h-index
- PT
2
h-index
1–5 of 170
Institutions
68
The University of Texas MD Anderson Cancer Center
Houston, United States
3 h-index
12 publications
1.1K citations
University of California San Diego
San Diego, United States
3 h-index
27 publications
6.8K citations
Dana-Farber Cancer Institute
Boston, United States
3 h-index
6 publications
214 citations
Harvard University
Cambridge, United States
3 h-index
4 publications
132 citations
National Cancer Institute
Bethesda, United States
2 h-index
10 publications
290 citations
Foundation Medicine (United States)
Cambridge, United States
2 h-index
8 publications
2.2K citations
Avera Health
Sioux Falls, United States
2 h-index
8 publications
2.9K citations
Thomas Jefferson University
Philadelphia, United States
2 h-index
2 publications
44 citations
1–8 of 68
Venues
- Journal of Clinical Oncology
2 publications · 33 citations
2
h-index
- Journal of Translational Medicine
JTM · 1 publications · 18 citations
1
h-index
- Journal of Controlled Release
1 publications · 71 citations
1
h-index
- Journal of Viral Hepatitis
1 publications · 51 citations
1
h-index
- Cancer Letters
1 publications · 17 citations
1
h-index
1–5